PTCT has 36-month beta value of 0.56. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 4 as “hold,” and 1 as “sell.”
The public float for PTCT is 76.80M, and currently, short sellers hold a 4.93% ratio of that float. The average trading volume of PTCT on March 14, 2025 was 714.64K shares.
PTCT) stock’s latest price update
PTC Therapeutics Inc (NASDAQ: PTCT)’s stock price has soared by 5.09 in relation to previous closing price of 52.76. Nevertheless, the company has seen a gain of 5.43% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-09 that PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC’s diversified pipeline, including vatiquinone for Friedreich’s ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market.
PTCT’s Market Performance
PTC Therapeutics Inc (PTCT) has experienced a 5.43% rise in stock performance for the past week, with a 13.32% rise in the past month, and a 10.91% rise in the past quarter. The volatility ratio for the week is 4.29%, and the volatility levels for the past 30 days are at 5.22% for PTCT. The simple moving average for the last 20 days is 6.75% for PTCT’s stock, with a simple moving average of 37.03% for the last 200 days.
Analysts’ Opinion of PTCT
Many brokerage firms have already submitted their reports for PTCT stocks, with BofA Securities repeating the rating for PTCT by listing it as a “Neutral.” The predicted price for PTCT in the upcoming period, according to BofA Securities is $55 based on the research report published on March 11, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $55. The rating they have provided for PTCT stocks is “Sector Perform” according to the report published on March 07th, 2025.
Morgan Stanley gave a rating of “Overweight” to PTCT, setting the target price at $67 in the report published on December 13th of the previous year.
PTCT Trading at 14.18% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.28% of loss for the given period.
Volatility was left at 5.22%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares surge +11.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.88% upper at present.
During the last 5 trading sessions, PTCT rose by +5.21%, which changed the moving average for the period of 200-days by +48.73% in comparison to the 20-day moving average, which settled at $51.93. In addition, PTC Therapeutics Inc saw 22.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Okey Stephanie, who proposed sale 5,000 shares at the price of $54.00 back on Mar 13 ’25. After this action, Okey Stephanie now owns shares of PTC Therapeutics Inc, valued at $270,000 using the latest closing price.
Boulding Mark Elliott, the EXEC. VP AND CLO of PTC Therapeutics Inc, sale 68,039 shares at $53.09 during a trade that took place back on Mar 10 ’25, which means that Boulding Mark Elliott is holding 103,901 shares at $3,611,982 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.86 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.45. The total capital return value is set at -0.26.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated 1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at -2.25. The interest coverage ratio of the stock is -1.77.
Currently, EBITDA for the company is -120.46 million with net debt to EBITDA at -13.52. When we switch over and look at the enterprise to sales, we see a ratio of 7.48. The receivables turnover for the company is 5.09for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
To put it simply, PTC Therapeutics Inc (PTCT) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
